Trial Profile
A Randomized Double Blind-placebo Controlled Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 in Participants With Ankylosing Spondylitis (AS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms ALIGN
- Sponsors Sanofi
- 18 Feb 2014 Results published in the Annals of the Rheumatic Diseases.
- 30 Oct 2013 Tolerability results from a post hoc analysis presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 06 Aug 2012 Actual patient number changed from 300 to 301 as reported by ClinicalTrials.gov (Parent trial: NCT01061723).